Newsroom
Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR
- Avidity Effect of a Single – Chain Multispecific Centyrin Results in Potent Inhibition of Tumors Expressing MET and EGFR Receptors
- Multispecific EGFR/MET Centyrin may have broad utility beyond NSCLC in patient populations in which tumors are primarily driven by EGFR and MET
Philadelphia, PA, April 2, 2019 --- Aro Biotherapeutics, a biotechnology company focused on the research and development of Centyrins to transform the treatment of cancer and other serious diseases, has announced the acceptance of its poster, entitled, “ABX9xx: A bispecific centyrin that synergizes to attenuate intracellular signaling in MET/EGFR positive tumors,” at the American Association for Cancer Research’s 2019 Annual Meeting. The poster will be presented on Wednesday, April 3, 2019 at the Georgia World Congress Center in Exhibit Hall B.
“Aro has been in existence for just over a year, and so we are very pleased to have quickly generated exciting new data that meets the AACR standards for presentation in such a short period of time,” said Sue Dillon, PhD, Co-founder and Chief Executive Officer of Aro. “Our proprietary lead program, which we’re referring to as the ABX900 Series, leverages many of the unique biophysical properties of Centyrins, which are small, simple, ultra-stable and ultra-soluble proteins. With the unique binding characteristics, biodistribution and efficient manufacturing in E. coli, we believe that ABX900 will be well differentiated vs bi-specific mAbs and small molecules that target the EGFR and MET receptors. For example, we have shown that ABX900 achieves potent anti-proliferative activity against a variety of tumors expressing MET and EGFR mutations, amplified MET and WT receptors, many of which are resistant to Tagrisso®.”
Building a Pipeline of Life Changing Therapies
Centyrins are small, structurally simple, ultra-stable, highly soluble proteins. These characteristics enable the discovery of medicines with new mechanisms of action for cancer and other devastating diseases. Aro’s lead program, which is a bi-specific Centyrin, is in late-stage lead optimization for advanced non-small cell lung cancer. Aro’s second therapeutic program is focused on creating a Centyrin-siRNA conjugate for other forms of cancer. This first-of-its-kind combination is designed to address unmet medical needs by targeting drug payloads in high concentration to the site of disease, while lowering the toxicity to non-target organs. The company holds an exclusive worldwide license for research, development, manufacturing and commercialization of Centyrin protein therapeutics.
About Aro Biotherapeutics
Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for delivery of a variety of drug payloads, including nucleic acid drugs for a diverse set of diseases. For more information, visit www.arobiotx.com.
Media Contact
Mike Beyer
Sam Brown Inc.
312-961-2502